Logo
  • About
    • What We Do
    • Team
    • Partners
  • Pipeline
  • Technologies
    • FastPharming®
    • Glycaneering℠
    • LicKM
    • VLP
  • Products
  • Resources
    • News
    • Events
    • Media
    • Scientific Content
  • Careers
  • Investors
  • Contact
  • Therapeutics
    • Oncology
      • IBIO-101
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-202
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Bioanalytics
    • mAb Solutions
    • Aseptic Fill/Finish
    • Factory Solutions
Investors

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
    • Presentations
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Data
    • Quote
    • Historical Data
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
Dec 22, 2021 9:25am EST

iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022

Dec 21, 2021 9:20am EST

iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting

Dec 10, 2021 8:30am EST

iBio Announces Partial Adjournment of Annual Meeting to December 22

Nov 30, 2021 8:00am EST

ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting

Nov 29, 2021 8:45am EST

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

Nov 17, 2021 4:30pm EST

Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting

Nov 15, 2021 4:05pm EST

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

Nov 15, 2021 1:00pm EST

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

Nov 08, 2021 4:30pm EST

iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

Nov 03, 2021 4:47pm EDT

iBio Acquires FastPharming Manufacturing Facility®

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …15
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Footer Logo
  • Therapeutics
    • Oncology
      • IBIO-101
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-202
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • mAb Solutions
    • Factory Solutions

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807

(979) 446-0027
LinkedIn
info@ibioinc.com
RSS News Feed

© 2022 iBio. All Rights Reserved.
Privacy Policy
Terms and Conditions

  • About
  • Pipeline
  • Technologies
  • Products
  • Resources
  • Careers
  • Investors
  • Contact